Multiple mechanisms are responsible for transactivation of the epidermal growth factor receptor in mammary epithelial cells.
The number of distinct signaling pathways that can transactivate the epidermal growth factor receptor (EGFR) in a single cell type is unclear. Using a single strain of human mammary epithelial cells, we found that a wide variety of agonists, such as lysophosphatidic acid (LPA), uridine triphosphate, growth hormone, vascular endothelial growth factor, insulin-like growth factor-1 (IGF-1), and tumor necrosis factor-alpha, require EGFR activity to induce ERK phosphorylation. In contrast, hepatocyte growth factor can stimulate ERK phosphorylation independent of the EGFR. EGFR transactivation also correlated with an increase in cell proliferation and could be inhibited with metalloprotease inhibitors. However, there were significant differences with respect to transactivation kinetics and sensitivity to different inhibitors. In particular, IGF-1 displayed relatively slow transactivation kinetics and was resistant to inhibition by the selective ADAM-17 inhibitor WAY-022 compared with LPA-induced transactivation. Studies using anti-ligand antibodies showed that IGF-1 transactivation required amphiregulin production, whereas LPA was dependent on multiple ligands. Direct measurement of ligand shedding confirmed that LPA treatment stimulated shedding of multiple EGFR ligands, but paradoxically, IGF-1 had little effect on the shedding rate of any ligand, including amphiregulin. Instead, IGF-1 appeared to work by enhancing EGFR activation of Ras in response to constitutively produced amphiregulin. This enhancement of EGFR signaling was independent of both receptor phosphorylation and PI-3-kinase activity, suggestive of a novel mechanism. Our studies demonstrate that within a single cell type, the EGFR autocrine system can couple multiple signaling pathways to ERK activation and that this modulation of EGFR autocrine signaling can be accomplished at multiple regulatory steps.
Rodland
Karin D
KD
Systems Biology Program, Pacific Northwest National Laboratory, Richland, Washington 99354, USA. karin.rodland@pnl.gov
Bollinger
Nikki
N
Ippolito
Danielle
D
Opresko
Lee K
LK
Coffey
Robert J
RJ
Zangar
Richard
R
Wiley
H Steven
HS
D002460:Cell Line; D004789:Enzyme Activation; D004847:Epithelial Cells / Q000378:metabolism*; D066246:ErbB Receptors / Q000819:agonists / Q000235:genetics* / Q000378:metabolism*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology; D007700:Kinetics; D008024:Ligands; D020935:MAP Kinase Signaling System / Q000187:drug effects; D042361:Mammary Glands, Human / Q000378:metabolism*; D010447:Peptide Hydrolases / Q000378:metabolism; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D013379:Substrate Specificity; D015533:Transcriptional Activation / Q000235:genetics*
D008024:Ligands; D007334:Insulin-Like Growth Factor I; D019869:Phosphatidylinositol 3-Kinases; D066246:ErbB Receptors; D010447:Peptide Hydrolases
Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):4995-5000
10220407
Nature. 1999 Dec 23-30;402(6764):884-8
10622253
Oncogene. 2007 May 14;26(22):3113-21
17496910
Oncogene. 2000 Nov 20;19(49):5690-701
11114749
Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15368-73
9860975
Ann N Y Acad Sci. 2003 May;995:22-38
12814936
EMBO J. 1997 Dec 1;16(23):7032-44
9384582
J Biol Chem. 2002 Jul 5;277(27):24252-7
11983694
Breast Cancer Res Treat. 1998;52(1-3):125-36
10066077
J Cell Biol. 2002 Jul 22;158(2):221-6
12119356
Proc Natl Acad Sci U S A. 1999 May 25;96(11):6235-40
10339571
Shock. 1997 Jun;7(6):427-31
9185243
Biochem Soc Trans. 2003 Dec;31(Pt 6):1203-8
14641026
Biol Chem. 2005 Sep;386(9):845-55
16164409
Oncogene. 2001 Mar 26;20(13):1594-600
11313906
J Biol Chem. 2003 May 23;278(21):19118-26
12642580
Oncogene. 1997 Feb 6;14(5):623-5
9053862
J Biol Chem. 2003 Aug 22;278(34):31574-83
12771142
Cancer Res. 2004 Sep 1;64(17):6166-73
15342401
EMBO J. 2003 May 15;22(10):2411-21
12743035
Cancer Surv. 1993;18:7-34
8013001
J Biol Chem. 2000 Jul 21;275(29):22583-9
10807918
Stem Cell Rev. 2007 Jan;3(1):7-17
17873377
J Biol Chem. 1995 Jan 20;270(3):1015-9
7836353
Biophys J. 2005 Apr;88(4):2384-90
15653719
J Biol Chem. 2005 Feb 18;280(7):6157-69
15572377
Dev Biol. 2002 Oct 15;250(2):305-16
12376105
Mol Biol Cell. 2002 Jun;13(6):2031-44
12058067
Exp Cell Res. 2003 Nov 1;290(2):437-46
14568001
Cancer Treat Res. 1988;40:1-24
2908646
Mol Cell Biol. 2008 Jan;28(2):587-600
18025104
Curr Top Dev Biol. 2003;54:101-23
12696747
Exp Cell Res. 2005 Aug 15;308(2):439-45
15950968
Arterioscler Thromb Vasc Biol. 2006 Sep;26(9):e133-7
16840716
Proc Natl Acad Sci U S A. 1989 Feb;86(4):1249-53
2919173
Proteomics. 2005 Apr;5(5):1263-73
15742320
EMBO J. 1999 Dec 15;18(24):6962-72
10601018
J Biol Chem. 2004 Apr 30;279(18):18488-96
14978035
J Biol Chem. 2003 Apr 4;278(14):12055-63
12556529
Trends Pharmacol Sci. 1999 Oct;20(10):408-12
10577253
Biochem J. 2002 Apr 15;363(Pt 2):211-21
11931648
Mol Cell Proteomics. 2005 Sep;4(9):1240-50
15951569
Oncogene. 2004 Jan 29;23(4):991-9
14647423
Mol Biol Cell. 2005 Jun;16(6):2984-98
15829568
Mol Endocrinol. 2004 Nov;18(11):2727-39
15272055
J Biol Chem. 2000 Jan 7;275(1):557-64
10617651
J Proteome Res. 2004 Jan-Feb;3(1):68-75
14998165
J Biol Chem. 2001 Jun 22;276(25):23155-60
11290747
Int J Cancer. 2002 Dec 20;102(6):572-9
12447997
Biophys J. 2006 Jun 1;90(11):3993-4009
16533841
Cancer Res. 2000 Sep 15;60(18):5310-7
11016663
Trends Cell Biol. 2003 Jan;13(1):43-50
12480339
Surgery. 2005 Sep;138(3):415-21
16213893
Mol Syst Biol. 2006;2:54
17016520